<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03137030</url>
  </required_header>
  <id_info>
    <org_study_id>HP7014-02</org_study_id>
    <secondary_id>U1111-1184-8922</secondary_id>
    <nct_id>NCT03137030</nct_id>
  </id_info>
  <brief_title>A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults</brief_title>
  <official_title>A Relative Bioavailability Trial to Investigate the Pharmacokinetics of Different Amounts of Tablets of Two Immediate Release Fixed Dose Combinations of Hydrocodone Bitartrate 5 mg/Acetaminophen 325 mg (a New Abuse Deterrent Tablet and a Marketed Tablet) Under Fasted Conditions in Healthy Male and Female Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gr端nenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gr端nenthal GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is being conducted to compare concentrations of hydrocodone and&#xD;
      acetaminophen in the blood after administration of different amounts of tablets of a new and&#xD;
      a marketed tablet formulation in healthy adults.&#xD;
&#xD;
      Part 1 is a randomized, single-site, open-label, 4-treatment, 4-period crossover, single oral&#xD;
      dose Phase I trial in 32 healthy male and female subjects. Part will consist of an Enrollment&#xD;
      Visit, 4 treatment periods (each lasting approximately 90 hours), and a Final Examination.&#xD;
      The treatment periods will be separated by a washout period each lasting at least 7 days.&#xD;
&#xD;
      Part 2 is optional and depending on pharmacokinetic data review after Part 1. It is a&#xD;
      randomized, single-site, open-label, 2-treatment, 2-period crossover, single oral dose part&#xD;
      in healthy male and female subjects. Part 2 will consist of an Enrollment Visit, 2 treatment&#xD;
      periods (each lasting approximately 90 hours) and a Final Examination. The treatment periods&#xD;
      will be separated by a washout period lasting at least 7 days.&#xD;
&#xD;
      Participants must fast for approximately 10 hours prior to administration of Investigational&#xD;
      medicinal product (IMP) and until approximately 4 hours after the administration of the IMP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    program discontinued&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>For Part 1, the randomization will be realized using a Williams Square with a 4x4 design. For the optional Part 2, a standard 2x2 crossover design will be applied.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) GRT7014 (1 and 10 Tablets)</measure>
    <time_frame>Between 0 hours and 72 hours</time_frame>
    <description>The maximum plasma concentration of hydrocodone and of acetaminophen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration curve from timepoint 0 to t (AUC0-t) GRT7014 (1 and 10 Tablets)</measure>
    <time_frame>Between 0 hours and 72 hours</time_frame>
    <description>The area under the plasma concentration curve of hydrocodone and of acetaminophen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration curve from timepoint 0 to infinity (AUC) GRT7014 (1 and 10 Tablets)</measure>
    <time_frame>Between 0 hours and 72 hours</time_frame>
    <description>The area under the plasma concentration curve of hydrocodone and of acetaminophen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) GRT7014 and Norco (1, 5 (optional) and 10 Tablets)</measure>
    <time_frame>Between 0 hours and 72 hours</time_frame>
    <description>The maximum plasma concentration of hydrocodone and of acetaminophen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration curve from timepoint 0 to t (AUC0-t) GRT7014 and Norco (1, 5 (optional) and 10 Tablets)</measure>
    <time_frame>Between 0 hours and 72 hours</time_frame>
    <description>The area under the plasma concentration curve of hydrocodone and of acetaminophen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration curve from timepoint 0 to infinity (AUC) GRT7014 and Norco (1, 5 (optional) and 10 Tablets)</measure>
    <time_frame>Between 0 hours and 72 hours</time_frame>
    <description>The area under the plasma concentration curve of hydrocodone and of acetaminophen.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Pain, Acute</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>GRT7014 - 1 Tablet (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.&#xD;
(GRT7014 - Abuse Deterrend Tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GRT7014 - 10 Tablets (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.&#xD;
(GRT7014 - Abuse Deterrend Tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norco - 1 Tablet (Part 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norco - 10 Tablets (Part 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GRT7014 - 5 Tablets (Optional Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.&#xD;
(GRT7014 - Abuse Deterrend Tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norco - 5 Tablets (Optional Part 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRT7014 - Abuse Deterrend Tablet</intervention_name>
    <description>Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.</description>
    <arm_group_label>GRT7014 - 1 Tablet (Part 1)</arm_group_label>
    <arm_group_label>GRT7014 - 10 Tablets (Part 1)</arm_group_label>
    <arm_group_label>GRT7014 - 5 Tablets (Optional Part 2)</arm_group_label>
    <other_name>Hydrocodone bitartrate and acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norco 5Mg-325Mg Tablet</intervention_name>
    <description>Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.</description>
    <arm_group_label>Norco - 1 Tablet (Part 1)</arm_group_label>
    <arm_group_label>Norco - 10 Tablets (Part 1)</arm_group_label>
    <arm_group_label>Norco - 5 Tablets (Optional Part 2)</arm_group_label>
    <other_name>Hydrocodone bitartrate and acetaminophen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects have given written informed consent to participate.&#xD;
&#xD;
          -  Body mass index between 20 kg/m2 and 30 kg/m2 inclusive, with a minimal body weight of&#xD;
             60 kg.&#xD;
&#xD;
          -  Subjects must be in good health as determined by the medical history, physical and&#xD;
             laboratory examinations and must not show any clinically significant deviations from&#xD;
             reference ranges as determined by 12-lead electrocardiogram (ECG), vital signs (blood&#xD;
             pressure, pulse rate, respiratory rate), body temperature, oxygen saturation, and&#xD;
             safety laboratory parameters (hematology, clinical chemistry, clotting, and&#xD;
             urinalysis).&#xD;
&#xD;
          -  From the first administration of IMP until at least 4 weeks (for women)/90 days (for&#xD;
             men) after the Final Examination, subjects must agree to use highly effective&#xD;
             contraception with a low failure rate defined as &lt;1% per year.&#xD;
&#xD;
          -  For female subjects of childbearing potential:&#xD;
&#xD;
               -  Combined (estrogen and progestogen containing) hormonal contraception.&#xD;
&#xD;
               -  Progestogen-only hormonal contraception associated with inhibition of ovulation.&#xD;
&#xD;
               -  An intra-uterine device (hormone-free).&#xD;
&#xD;
               -  An intra-uterine hormone releasing system (IUS).&#xD;
&#xD;
               -  Bilateral tubal occlusion.&#xD;
&#xD;
        Women of non-childbearing potential may be included if surgically sterile (i.e., after&#xD;
        hysterectomy or bilateral oophorectomy) or post-menopausal for at least 12 months (i.e.,&#xD;
        spontaneous amenorrhea at least 1 year prior to screening with confirmed&#xD;
        follicle-stimulating hormone level &gt;40 IU/L).&#xD;
&#xD;
        For male subjects:&#xD;
&#xD;
        Male subjects have to use barrier contraception (condom) during sexual intercourse with&#xD;
        women of childbearing potential from the first application of IMP until at least 90 days&#xD;
        after the Final Examination. The male subject has to be willing to ensure that the female&#xD;
        sexual partner uses at least 1 additional method of contraception with a low failure rate&#xD;
        defined as &lt;1% per year until at least 90 days after the Final Examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Withdrawal of informed consent.&#xD;
&#xD;
          -  Received forbidden medication or an investigational medical device since the&#xD;
             Enrollment Visit.&#xD;
&#xD;
          -  Any relevant deterioration in the health of the subject since the Enrollment Visit&#xD;
             possibly impacting participation in the trial at the discretion of the investigator,&#xD;
             including: adverse events; vital signs (relevant out-of-reference blood pressure or&#xD;
             pulse rate if technical failure can be excluded and result is confirmed by at least 1&#xD;
             additional measurement); physical examination, 12-lead ECG (relevant QTc prolongation&#xD;
             if result is confirmed by 1 additional ECG measurement and manual re-evaluation by the&#xD;
             investigator); other safety parameters.&#xD;
&#xD;
          -  Blood loss of 100 mL or more since enrollment in this trial (excluding blood taken for&#xD;
             this trial).&#xD;
&#xD;
          -  Resting pulse rate &lt;50 beats per minute or &gt;90 beats per minute.&#xD;
&#xD;
          -  Resting systolic blood pressure &lt;90 mmHg or &gt;140 mmHg. Resting diastolic blood&#xD;
             pressure &gt;90 mmHg.&#xD;
&#xD;
          -  Prolongation of corrected QT interval (according to Fridericia's formula; QTcF), i.e.,&#xD;
             QTcF &gt;450 ms or presence of other of risk factors for torsade de pointes.&#xD;
&#xD;
          -  Evidence for thyroid disease based on clinical and safety laboratory findings,&#xD;
             including thyroid-stimulating hormone.&#xD;
&#xD;
          -  Any laboratory value (from blood samples taken at the Enrollment Visit) meeting the&#xD;
             following criteria:&#xD;
&#xD;
               -  Out-of-reference range value for alanine transaminase, aspartate transaminase,&#xD;
                  alkaline phosphatase, total bilirubin, glucose (fasted), gamma-glutamyl&#xD;
                  transferase, serum creatinine, prothrombin time, and international normalized&#xD;
                  ratio.&#xD;
&#xD;
               -  Exclusion range met for urinalysis or lactate dehydrogenase, potassium, total&#xD;
                  protein, sodium, calcium, hemoglobin, hematocrit, white blood cell count, or&#xD;
                  platelets.&#xD;
&#xD;
               -  Out-of-reference range value for any other safety laboratory parameter that is&#xD;
                  judged as clinically relevant by the investigator.&#xD;
&#xD;
               -  A single repeat laboratory test (for each out-of-range parameter) is allowed to&#xD;
                  rule out laboratory error.&#xD;
&#xD;
          -  Positive or missing virus serology test (in blood sample taken at the Enrollment&#xD;
             Visit) for human immunodeficiency virus Type 1 or Type 2 antibodies, hepatitis B&#xD;
             surface antigen, (HBsAg), hepatitis B core antigen antibodies (anti-HBc), or hepatitis&#xD;
             C virus antibodies.&#xD;
&#xD;
          -  For women of childbearing potential only: positive or missing pregnancy test.&#xD;
&#xD;
          -  Subject received IMP in another clinical trial (when assessing for Part 2, excludes&#xD;
             IMP received in Part 1 of this trial) within 30 days before the Enrollment Visit.&#xD;
             Depending on the nature of the previous IMP, a longer washout may be needed.&#xD;
&#xD;
          -  Diseases or conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of drugs.&#xD;
&#xD;
          -  History of orthostatic hypotension.&#xD;
&#xD;
          -  History of, or at risk of seizures (i.e., head trauma, epilepsy in family history,&#xD;
             unclear loss of consciousness).&#xD;
&#xD;
          -  Definite or suspected hypersensitivity to the active substance or to any of the&#xD;
             excipients of the IMP; especially known hypersensitivity/intolerance or&#xD;
             contraindications to opioids, opioid antagonists, acetaminophen or any excipients of&#xD;
             the drug formulation.&#xD;
&#xD;
          -  Evidence or history of alcohol or drug abuse including positive or missing alcohol&#xD;
             breath test or drugs of abuse test.&#xD;
&#xD;
          -  Unable to abstain from regular use of any medication, including herbal remedies or&#xD;
             over-the-counter medication within 2 weeks prior to the Enrollment Visit and&#xD;
             anticipated use during the course of the trial, excluding oral contraceptives in women&#xD;
             of childbearing potential and topical medications or nasal sprays without systemic&#xD;
             effect.&#xD;
&#xD;
          -  Lactating or breastfeeding women.&#xD;
&#xD;
          -  Habitually smoking more than 10 cigarettes, 2 cigars, or 2 pipes of tobacco per day&#xD;
             within the last 6 months before enrollment in this trial.&#xD;
&#xD;
          -  Unable to refrain from smoking during the stay at the trial site in each treatment&#xD;
             period.&#xD;
&#xD;
          -  Not willing or able to abstain from consumption of:&#xD;
&#xD;
               -  Beverages or food containing methylxanthines (tea, coffee, cola, chocolate, etc.)&#xD;
                  from 48 hours prior to the planned first administration of IMP until discharge&#xD;
                  from the trial site in each treatment period.&#xD;
&#xD;
               -  Beverages or food containing quinine (bitter lemon, tonic water), grapefruit&#xD;
                  juice (sweet or sour), Seville oranges, or alcohol from 72 hours prior to the&#xD;
                  planned first administration of IMP until discharge from the trial site in each&#xD;
                  treatment period.&#xD;
&#xD;
          -  Known or suspected of not being able to comply with the requirements of the trial&#xD;
             protocol or the instructions of the trial site staff.&#xD;
&#xD;
          -  Not able to communicate meaningfully with the trial site staff.&#xD;
&#xD;
          -  Employee of the investigator or trial site, with direct involvement in the proposed&#xD;
             trial or other trials under the direction of that investigator or trial site, as well&#xD;
             as family members of the employees or the investigator.&#xD;
&#xD;
          -  Blood loss of 500 mL or more within 45 days before enrollment in this trial.&#xD;
&#xD;
          -  Unable to establish reliable venous access.&#xD;
&#xD;
          -  Medical history of bronchial asthma, Addison's disease, prostatic hypertrophy, or&#xD;
             urethral stricture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gr端nenthal Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gr端nenthal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US001: PRA Health Sciences</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abuse deterrent formulation</keyword>
  <keyword>Hydrocodone</keyword>
  <keyword>Analgesics, Opioid</keyword>
  <keyword>Narcotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Details available at:&#xD;
http://www.grunenthal.com/grt-web/Grunenthal_Group/Research_Development/Grunenthal_Clinical_Trials/Data_Sharing/296200025.jsp</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

